Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 1998

View Archived Issues

Company Profile: Acacia Biosciences

Orally active enkephalinase-inhibitory prodrug reported by Dainippon

SmithKline Beecham presents new azetidinones for atherosclerosis

Inhibitors of prostaglandin biosynthesis prepared at Abbott

Enantiomers of trans-benz[e]indoles selective for D3 receptors

Lilly prepares compounds for controlling TxA2

Anti-H. pylori agents from Pfizer

Princeton and Lilly collaborate on development of inhibitors of folate enzymes

CRF antagonists patented by Pfizer

Irreversible HIV protease inhibitors under evaluation at LG Chemical

Novel bone resorption inhibitors from ADIR

Desmycosin derivatives a focus of research at Pliva

TNF-alpha inhibitors disclosed by Celgene

New telomerase inhibitors from Geron

Merck & Co. describes FPTase inhibitors with improved pharmacokinetics

New class of macrolides developed at Abbott

Ontogen describes novel MDR modulators

Efficacy and safety of oral contraception demonstrated in men

Abbott presents in vitro and in vivo efficacy data on tricyclic ketolides

Lexacalcitol: a vitamin D analogue with increased potency

Clinical results reported for Servier's MDR-reversing agent S-9788

HMR's new ketolides extensively discussed at conference this week

T Cell Sciences awarded SBIR grant for atherosclerosis vaccine

Viracept approved for marketing in E.U. member countries

Alkermes, Johnson & Johnson to codevelop novel formulation of erythropoietin

Boston Life Sciences to seek U.S. approval for Therafectin

Antegren meets development criteria in phase II trial

Quilimmune-P enters phase II

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...